GOODWILL AND INTANGIBLE ASSETS (Tables)

12 Months Ended

Dec. 31, 2023

Disclosure Of Goodwill And Intangible Assets [Abstract]

Schedule of Goodwill and Intangible Assets

	Goodwill US$‘000			Development costs US$‘000			Patents and licenses US$‘000			Other US$‘000			Total US$‘000
Cost
At January 1, 2022		79,182			121,173			8,707			33,198			242,260
Additions					4,475			22			382			4,879
Exchange adjustments		-			(64	)		-			-			(64	)
At December 31, 2022		79,182			125,584			8,729			33,580			247,075
At January 1, 2023		79,182			125,584			8,729			33,580			247,075
Additions		-			1,758			19			110			1,887
Disposals or retirements		(12,591	)		-			-			(14,488	)		(27,079	)
Reclassifications		54			-			(54	)		-			-
Exchange adjustments		-			23			-			-			23
At December 31, 2023		66,645			127,365			8,694			19,202			221,906
Accumulated amortisation and Impairment losses
At January 1, 2022		(66,645	)		(103,494	)		(8,561	)		(27,579	)		(206,279	)
Charge for the year					(479	)		(9	)		(435	)		(923	)
Impairment losses		-			(4,623	)		-			(1	)		(4,624	)
Exchange adjustments		-			20			-			-			20
At December 31, 2022		(66,645	)		(108,576	)		(8,570	)		(28,015	)		(211,806	)
At January 1, 2023		(66,645	)		(108,576	)		(8,570	)		(28,015	)		(211,806	)
Charge for the year		-			(753	)		30			(223	)		(946	)
Disposals or retirements		-			-			-			12,956			12,956
Impairment losses		-			(2,926	)		(9	)		(2,898	)		(5,833	)
Exchange adjustments		-			(7	)		-			-			(7	)
At December 31, 2023		(66,645	)		(112,262	)		(8,549	)		(18,180	)		(205,636	)
Carrying amounts
At December 31, 2023		-			15,103			145			1,022			16,270
At December 31, 2022		12,537			17,008			159			5,565			35,269

Schedule of Principal Development Projects

Product Name	2023  US$’000		2022  US$’000
Premier Instruments for A1c and haemoglobinopathies testing		1,669		1,904
COVID-19 tests		-		1,378
Mid-tier haemoglobins instrument		51		484
HIV screening rapid test		6		379
Tri-stat point-of-care instrument		-		163
Other projects		32		167
Total capitalised development costs		1,758		4,475

Schedule of Impairment Loss Recorded on Discontinued Assets

	December 31,  2023		December 31,  2022
	US$’000		US$’000
Immco Diagnostics inc.		9,331		-
Trinity Biotech Manufacturing Limited (Note 13)		1,500		3,599
Trinity Biotech Do Brasil		274		454
Primus Corp		-		1,024
Clark Laboratories Inc.		-		407
Biopool US Inc.		-		355
Total impairment loss		11,105		5,839

Schedule of Impairment Loss for Each Class of Asset

	December 31,  2023		December 31,  2022
	US$’000		US$’000
Goodwill and other intangible assets		5,833		4,624
Property, plant and equipment (see Note 11)		3,772		733
Financial assets (see Note 13)		1,500		-
Prepayments (see Note 17)		-		482
Total impairment loss		11,105		5,839

Schedule of Specific Asset Impairment Charges

Asset name	Entity	2022 US$’000
Rapid COVID-19 antigen test	Trinity Biotech Manufacturing Ltd		2,214
Autoimmune smart reader	Trinity Biotech Manufacturing Ltd		1,266
Tri-stat instrument	Primus Corp.		1,024
COVID-19 ELISA test	Trinity Biotech Manufacturing Ltd		120
Total			4,624

Schedule of Significant Goodwill

Fitzgerald Industries	December 31, 2022
Carrying amount of goodwill (US$’000)		12,591
Discount rate applied (real pre-tax)		15.77	%
Excess value-in-use over carrying amount (US$’000)		7,432
% EBITDA would need to decrease for an impairment to arise		31.28	%
Long-term growth rate		2.0	%

Schedule of Internal and External Factors Based on Historical Experience

Intangible Assets with Indefinite Useful lives (included in other intangibles)	December 31, 2023 US$‘000		December 31, 2022 US$‘000
Immco Diagnostic CGU
Immco Diagnostic trade name		-		2,069
Fitzgerald Industries CGU
Fitzgerald trade name		-		970
RDI trade name		-		560
Primus Corporation CGU
Primus trade name		365		365
Total		365		3,964